Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added Merck to the The Generex/NGIO breast cancer study is a combo of NGIO's AE37 and Merck's Keytruda. under #4 in the I-Box
updates in the I-Box
include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Funding is there, building will be built, dots will stop counterfeiters. Patience is the key.
I have followed the company for awile not your ave OTC they are for real. You will do quite well. I have been holding 5K shares and pleasantly surprised with the headline. I plan to buy more 2morrow. Ck out my posts on GNBT and docj sticky.
Correct statement regarding restricted shares being sold dropping the price hard. Its a new better day here at GNBT. Not a typical OTC it has NASDAQ clout.
Dividend for NuGenerex Immuno-Oncology (NGIO) happened also.
The Indian QD Plant will happen just like me being patient with Generex :)
Never left been quiet for awile. Between the Dividend and Todays Excellent News. For Real my friend :)
Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS.
Shares Outstanding 51,076,984
Shares Outstanding Date 02/20/2020
Great DD Post Sticky if you could. Getting exposure to the broader market :)
Market is ugly outside OTC's and a select few corona plays. Waiting on MILV and looking forward to that run.
Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
Terms approved to proceed with collaborative effort with international consortium
MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.
Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
Been sitting in my portfolio then POP!!!
Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
Terms approved to proceed with collaborative effort with international consortium
MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.
Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
Terms approved to proceed with collaborative effort with international consortium
MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.
Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
It Came Alive & Dividend :)
Many stop losses hit due to the corona virus fears in the market. This may also be the "correction" needed to go higher. New $$ will hold at this level.
The better news is corona virus has a mortality rate of less then 2%.
We can go back up quickly. Not concerned longer term. Clay Trader video helpful
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154038299
The Dow Dropping 1900 Points had nothing to do with a selloff LOL.
VG is amazing and so our it's investors :)
Its up to QMC to succeed.
I no longer read responses why bother
March ‘19 QMC receives $500K upfront licensing fee for Assam, India solar project,
April ‘19 QMC unveils industry first 100% cadmium free, RoHS compliant, quantum dot LCD display film with 95% Rec. 2020 color gamut coverage,
June ‘19 QMC announces $1Million equipment order for Assam India solar project,
July ‘19 QMC announces expansion of Assam India solar project in update,
August ‘19 QMC acquires Capstan Platform Inc. a leader in blockchain platform design to build QMC's anti-counterfeit product line. Jay Williams a long-time technology pioneer and architect joins QMC as Chief Technology Officer,
September ‘19 QMC establishes a business advisory board with deep experience and networks spanning supply chain, national security, government, technology, consumer goods, finance and more,
September ‘19 QMC announces anti-counterfeit focus with QDX Ledger Blockchain Platform and new hire John Hartigan as Chief Revenue Officer,
October ‘19 QMC releases update on our Assam, India licensee’s solar project with increased volume and revenue projected for 2021 due to expansion from the original 20,000 sq. ft facility to 75,000 sq. Ft.,
November ‘19 QMC provides vision and market opportunities for the QDX Ledger Anti-counterfeit Platform in live webinar,
January '20 letter of intent signed for $2M equity investment and Joint Venture to form Quantum Materials Vertical Technologies, LLC.
QMC is alive and well. January update is convincing.
The past has nothing to do with now.
Why would Hartigan and Williams join a sinking ship?
A Letter of Credit: A letter issued by a bank to another bank (typically in a different country) to serve as a guarantee for payments made to a specified person under specified conditions.
Amtronics signed the License and Development Agreement. I guess that is not real either.
https://www.sec.gov/Archives/edgar/data/1403570/000149315219002055/ex10-1.htm
A 1M Letter of Credit is a 1M Letter of Credit. Any questions?
For all you know QMC may be working with an OEM in the display arena and going thru the final phases for QD production. You do not know and are guessing again. If QMC has not announced yet does not mean that it will not happen.
India got 2 Reactors. Hartigan mentioned Solar Revenue. Im sure those reactors are in a Building besides the one being built.
The working QD Reactor got India to say YES. Oh BTW.
Weed has invested or at least commented in the correct IPO's and SPAC's, his comments are on tract. IMO. We'll see, very opp about SPCE L/T.
Probably a very wealthy man burning one LOL.
Agreed, Patience is the key here. Progress "however slow" is being made. Their QD's and reactor are ready for production is the key.
Stock is consolidating added under 17 Fri dropping my ave. Still very under the radar for early "bettors". Found this last weekend.
Stock consolidating no major up/down movement today. Good sign for Longs.
Great point why is he picking on SPCE vs all the other overpriced equities out there.?
Touche'